Essex Bio-Technology (HKSE:01061) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01061 Essex Bio-Technology Ltd HKSE:01061
86 GF Score
Price HK$2.29
GF Value HK$3.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Essex Bio-Technology FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01061
86GF Score
Essex Bio-Technology Ltd HKSE:01061
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?

Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued. The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13. GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.

Key valuation signals for HKSE:01061:

  • FFO:
  • GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Essex Bio-Technology Business Description

Address No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score

Get the complete analysis for HKSE:01061

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.29
Price
HK$3.13
GF Value